fda compounding semaglutide crackdown news today 2025 Takes Aim at Hims & Hers, Weight-Loss Drugs in New Advertising Blitz FDA restricts non-approved compounded GLP-1

A probable explanation is that this finding reflects patients trying to delay hospital admission because of their fear of acquiring SARS-CoV-2 infection

Your GP may refer you to a hepatologist if your FIB-4 score suggests possible advanced fibrosis, if an Enhanced Liver Fibrosis (ELF) blood test shows a score of 10.51 or above, or if you have persistently abnormal liver function tests despite lifestyle changes

Key enforcement actions include: Issuance of advisories banning surrogate and indirect advertising of weight-loss drugs Nationwide inspections targeting pharmacies, distributors, and wellness centers Regulatory action and notices against entities violating prescription and marketing norms Authorities have reiterated that GLP-1 therapies must be prescribed strictly by qualified specialists, such as endocrinologists or internal medicine practitioners, and only for approved clinical indications

Department of Veterans Affairs and Washington University School of Medicine, their impact may extend even further than expected